Ask AI
ProCE Banner Activity

OPTI-AML: Phase II Trial of 28-Day vs 14-Day Venetoclax and Azacitidine for 2 Cycles in Patients Aged ≥60 Years with Newly Diagnosed Genomically Agnostic AML

Conference Coverage
Slideset

In patients 60 years of age or older with newly diagnosed genomically agnostic AML considered unfit for intensive chemotherapy, use of a 14-day schedule of venetoclax and azacitidine for 2 cycles did not demonstrate noninferiority to the standard 28-day schedule of venetoclax and azacitidine, with complete response rates appearing to differ by molecular subtype.

Released: July 01, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

This activity is supported by educational grants from Incyte Corporation, Lilly, and Novartis Pharmaceuticals Corporation.

Incyte Corporation

Lilly

Novartis Pharmaceuticals Corporation

Target Audience

This activity is intended for hematologists, oncologists, and other healthcare professionals who care for patients with hematologic malignancies. 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Integrate cutting-edge data from studies of hematologic malignancies at ASCO 2026 and EHA 2026 along with expert guidance to optimize personalized care and improve patient outcomes

  • Utilize prognostic and predictive biomarkers to accurately identify patients with hematologic malignancies most likely to benefit from specific targeted therapies and treatment strategies

  • Interpret newly released clinical data on novel agents, updated guidelines, and emerging therapeutic approaches for hematologic malignancies to accelerate their effective incorporation into clinical practice

  • Support informed shared decision-making for patients with hematologic malignancies through accessible discussion of the potential clinical implications of recently presented data at ASCO 2026 and EHA 2026